Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs
Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9…
Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs
Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug. The post Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs appeared first on MedCity News.
Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps. The post Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges appeared first on MedCity News.
Are We Entering an Interoperability Trust Recession?
Here’s what healthcare entities should know about the maturing landscape, what to actually be concerned about, and the next stage of healthcare data evolution as we know it. The post Are We Entering an Interoperability Trust Recession? appeared first on MedCity News.
Journalists Dig Into HHS’ Covid Injury List, ACA Sign-Ups, and Telehealth
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed the Department of Health and Human Services’ plan to offer compensation for automatic covid vaccine injuries and the drop in enrollment in Affordable Care Act health plans on CBS’ The Takeout With Major Garrett on July 10 and 9, respectively. Click here to watch Gounder…
Juno Bio Raises $3.8M to Support Vaginal Health
Juno Bio’s funding was supported by Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator. The post Juno Bio Raises $3.8M to Support Vaginal Health appeared first on MedCity News.
The ‘Bot Vs. Bot’ Dynamic Between Providers & Payers Is Driving Up Costs for Everyone
HSS chief digital and information officer Ashis Barad, who has worked on both the payer and provider sides of healthcare AI, thinks the industry’s growing “bot vs. bot” battle over prior authorizations and appeals is driving costs up. To him, the real fix lies in providers and payers sharing data to build more personalized care…
Behind the Scenes in Medicaid
Leaders emphasize collaboration and understanding system interdependencies
Elevance Preparing to Exit Several Medicaid States
Leaders of the parent of Anthem and Wellpoint recently agreed with D.C. officials to leave that jurisdiction and say they are focused on long-term financial sustainability.
GSK Drug From $2B Deal Sputters in Phase 3 Test in Chronic Cough
GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a setback to a program once hoped to yield a new blockbuster product for the company’s respiratory drug portfolio. The post GSK Drug From $2B Deal…
Navigating Responsible Adoption of Agentic AI in Healthcare
Effective adoption of agentic AI in healthcare hinges on understanding its interdependent layers, implementing responsible use practices like bias mitigation and explainability, and fostering organizational trust through deliberate, human-centered strategies.
